ENOB SHAREHOLDER ALERT: Jakubowitz Law Reminds Enochian Shareholders of a Lead Plaintiff Deadline of September 26, 2022

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Enochian BioSciences, Inc. (NASDAQ: ENOB).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/enochian-biosciences-inc-loss-submission-form/?id=30782&from=4

The lawsuit seeks to recover losses for shareholders who purchased Enochian between January 17, 2018 and June 27, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until September 26, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Enochian BioSciences, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE Jakubowitz Law

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED